OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. White on Ablative Radiotherapy for MBC

March 14th 2014

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the use of ablative radiotherapy in patients with metastatic breast cancer.

Dr. Lewis on Sequencing Strategies in Melanoma

March 14th 2014

Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing strategies for the treatment of melanoma.

Dr. Charles Ryan on Prescribing Preferences

March 13th 2014

Charles Ryan, MD, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma.

Dr. Bordonaro on the Treatment of Advanced CRC

March 13th 2014

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Dr. Wierda on the Treatment of Elderly CLL Patients

March 12th 2014

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment recommendations for patients with CLL.

Dr. Salerno on the Importance of Clinical Researchers

March 12th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, discusses federal funding for research and the importance of gaining funds though private philanthropy to support clinical researchers.

Dr. Plimack on an mTOR/HDAC Inhibitor Combination in RCC

March 11th 2014

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial that looked at overcoming mTOR resistance with an HDAC inhibitor in renal cell carcinoma (RCC).

Dr. Peeters on the Future of Colorectal Cancer

March 11th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.

Dr. Figlin on Intermediate Prognosis Patients With mRCC

March 5th 2014

Robert Figlin, MD, FACP, discusses an analysis of the heterogeneity of intermediate prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

Dr. Fine on GTX in Inoperable Pancreatic Cancer

March 5th 2014

Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses a phase II study that evaluated the efficacy of neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) in patients with inoperable pancreatic adenocarcinoma

Dr. Galsky on Biomarkers for Satraplatin in mCRPC

March 4th 2014

Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with mCRPC.

Dr. Ravandi on Resistance in AML

March 4th 2014

Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance in adults with acute myeloid leukemia.

Dr. Melnick on Epigenetic Diversity in DLBCL

March 3rd 2014

Ari Melnick, MD, professor of medicine, Weill Cornell Medical College, discusses the association between epigenetic diversity and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Leyland-Jones on Breast Cancer Risk Assessment Tools

March 3rd 2014

Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.

Dr. McDermott on Targeting PD-1/PD-L1 in Kidney Cancer

February 28th 2014

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Dr. Goy on the Challenges of Treating Hodgkin's Lymphoma

February 27th 2014

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.

Dr. Tripathy on Markers of Resistance in Breast Cancer

February 26th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses markers of resistance in patients with HER2+ breast cancer.

Dr. Erba on BCR-ABL Ratio After Imatinib in CML

February 25th 2014

Harry Erba, MD, PhD, discusses the frequency in which patients with chronic-phase chronic myeloid leukemia (CML) fail to achieve a BCR-ABL transcript level below 10% after 3 months of treatment with imatinib.

Dr. Fakih on Angiogenesis Versus EGFR Inhibitors in CRC

February 25th 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Dr. Yu Discusses the Utility of GTx-758 in mCRPC

February 24th 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in mCRPC.